NurExone Advances U.S. Manufacturing, Expands Mexico Distribution
Event summary
- NurExone signed a binding MOU with Made Scientific for U.S. GMP manufacturing collaboration, targeting initial exosome batches in H1 2027.
- Exo-Top entered into a binding MOU with ExoLyra for exclusive distribution rights in Mexico, including a $180K territorial exclusivity fee.
- ExoPTEN preclinical data showed statistically significant higher numbers of myelin-positive cells in spinal-cord-injury models.
- NurExone raised $1.2M in two private placements in Q2 2026 for working capital.
- Net loss for Q2 2026 was $1.68M, down from $1.85M in Q2 2025.
The big picture
NurExone is positioning itself for a pivotal phase in its development, with strategic manufacturing and distribution partnerships aimed at scaling its exosome-based therapies. The company's focus on U.S. GMP manufacturing and expanding commercial footprint in Mexico underscores its push toward regulatory milestones and potential clinical trials. The recent fundraising and cost management efforts reflect disciplined financial planning amid ongoing R&D investments.
What we're watching
- Manufacturing Scale-Up
- Whether NurExone can successfully transfer technology and produce GMP-compliant exosome batches by H1 2027.
- Regulatory Milestones
- The pace at which NurExone advances toward a potential IND submission for ExoPTEN in H1 2027.
- Commercial Execution
- How NurExone leverages its Mexico distribution deal to drive early revenue and market penetration.
Related topics